Our results showing the upregulated expression of SLC7A11 and GCLC genes could assume their compensatory activation toward the support of glutathione-related antioxidant effects on PBMCs in SP MS patients, which is in line with an absence of decrease in GPX4 levels. Here, SLC7A11 is linked to myeloid sarcoma.